1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
AbbVie Inc.

AbbVie Inc.

0QCV.IL
AbbVie Inc.GB flagInternational Order Book
256.50
USD
+6.00
- -
453.27BMarket Cap
AbbVie Inc.
0QCV.IL
(International Order Book)

Recent

price

256.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
9.68
10.79
11.66
11.84
12.54
14.2
16.1
17.72
22.15
22.49
25.95
31.78
32.81
30.76
31.91
34.57
36.4
Revenue per Share
2.59
2.12
3.34
2.6
1.11
3.2
3.74
3.33
3.85
5.33
2.62
6.53
6.69
2.75
2.42
2.39
3.57
Basic EPS, GAAP
2.8
3.65
3.81
3.64
1.85
4.35
4.12
5.92
8.65
8.64
9.51
12.44
13.71
12.49
10.1
10.07
10.29
Free Cash Flow per Basic Share
- -
- -
- -
1.61
1.67
2.05
2.33
2.58
3.77
4.3
4.37
5.24
5.68
5.97
6.25
6.59
6.77
Dividend per Share
9.94
7.55
2.13
2.83
1.09
2.45
2.91
3.2
-5.71
-5.53
7.41
8.71
9.75
5.87
1.88
-1.85
-3.36
Book Value per Share
3.68
1.85
-3.22
-2.32
-3.54
-17.97
-24.91
-24.02
-30.66
-28.69
-58.31
-52.55
-46.54
-43.91
-51.95
-51.79
-51.27
Tangible Book Value per Share
1,616
1,616
1,577
1,587
1,591
1,610
1,593
1,592
1,479
1,479
1,765
1,768
1,769
1,766
1,765
1,769
1,769
Basic Weighted Avg Shares
15,638
17,444
18,380
18,790
19,960
22,859
25,638
28,216
32,753
33,266
45,804
56,197
58,054
54,318
56,334
61,160
64,386
Sales/Revenue/Turnover
30.16
20.75
31.65
30.14
17.09
32.97
36.43
33.83
19.49
39.03
24.81
31.89
32.41
24.92
21.11
32.85
33.94
Operating Margin (%)
1,184
1,272
1,150
897
786
836
1,189
1,501
1,765
2,017
6,471
8,521
8,467
8,698
8,386
8,139
7,869
Depreciation Expense
4,178
3,433
5,275
4,128
1,774
5,144
5,953
5,309
5,687
7,882
4,616
11,542
11,836
4,863
4,278
4,226
6,310
Net Income, GAAP
13.61
6.41
7.86
22.58
25.12
22.59
24.49
31.29
- -
6.46
- -
11.09
12.11
22.03
- -
35.83
27.39
Effective Tax Rate (%)
26.72
19.68
28.7
21.97
8.89
22.5
23.22
18.82
17.36
23.69
10.08
20.54
20.39
8.95
7.59
6.91
9.8
Profit Margin (%)
4,457
1,457
8,578
10,969
4,688
5,420
6,406
4,582
-294
33,934
-4,488
-7,266
-1,075
-4,839
-13,167
-14,227
-7,973
Working Capital
- -
32
14,630
14,292
10,538
29,240
36,440
30,953
35,002
62,975
77,554
64,189
59,135
52,194
60,340
58,941
62,481
LT Debt
15,703
11,932
3,363
4,492
1,742
3,945
4,636
5,097
-8,446
-8,172
13,097
15,436
17,287
10,397
3,364
-3,228
-5,888
Total Equity
52.42
24.76
34.74
22.93
14.22
22.3
18.3
15.63
- -
26.89
- -
16.66
19.15
14.04
- -
19.13
23.45
Return on Invested Capital (%)
53.21
24.8
34.63
22.79
11.66
21.78
17.49
14.53
- -
21.13
- -
14.31
15.97
8.76
- -
9.02
12.45
Return on Capital (%)
53.21
24.85
68.98
105.11
56.91
180.9
138.75
109.09
- -
- -
- -
81.04
72.48
35.22
62.52
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8,555
8,326
8,341
LT Borrowings
58,941
64,532
62,481
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,768
1,767
1,767
Market Capitalization
406,611
384,264
449,719

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
29,062
33,529
33,669
Cash, Cash Equivalents & STI
5,257
9,391
6,569
Accounts Receivable, Net
12,589
12,479
13,824
Inventories
4,951
5,049
5,127
Total Current Liabilities
43,289
42,100
41,642
Payables & Accruals
34,734
33,774
33,301
ST Debt
8,555
8,326
8,341
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-77.54%
-54.72%
-195.96%
Free Cash Flow
11.73%
2.59%
-0.09%
Net Income, GAAP
8.96%
16.09%
-1.22%
Sales/Revenue/Turnover
10.94%
6.37%
8.57%
Total Cash Common Dividend
13.82%
8.75%
5.73%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,310
14,462
14,460
15,102
56,334
2025
13,343
15,423
15,776
16,618
61,160
2026
15,002
16,990
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.78
0.78
0.88
-0.01
2.42
2025
0.73
0.53
0.11
1.03
2.39
2026
0.39
2.04
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.57
1.56
1.56
1.56
6.25
2025
1.65
1.65
1.65
1.65
6.59
2026
1.74
1.74
- -
- -
- -
Similar Companies
Patidar Buildcon Limited (PATIDAR.BO)
China Health Group Inc. (8225.HK)
Global Pharmatech, Inc. (GBLP)
Tycoon Group Holdings Limited (3390.HK)
Albert David Limited (ALBERTDA.BO)
Redwood Scientific Technologies, Inc. (RSCI)
Business
AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and markets medicines and therapies across immunology, oncology, neuroscience, virology, and other disease areas, along with branded and generic pharmaceutical products and contract development and manufacturing services. The company provides a broad portfolio of prescription medicines, biologics, and consumer health products through pharmaceutical brands such as Humira (adalimumab), Imbruvica, Zyloprim, Creon, and Botox in related segments, complemented by a robust pipeline of investigational therapies and biosimilars. Main products and services: therapeutic biologics and small-molecule drugs for immunology, oncology, neuroscience, infectious diseases, and metabolic disorders; contract development and manufacturing services (CDMO) for biopharmaceuticals; research and development activities including clinical trial support, regulatory affairs expertise, and process development; commercialization and sales of prescription pharmaceuticals; portfolio management and lifecycle extension strategies; patient support programs; regulatory affairs and pharmacovigilance; manufacturing and quality control across global facilities; scientific advisory and medical information services; Kendall, AbbVie Medicine, Allergan Aesthetics, and other branded product lines through regional offices and distributors; biosimilars development and collaboration programs; over-the-counter and consumer health products in some markets; partnerships for drug discovery, development, and commercialization. Latest major company changes: expands collaboration agreements with biopharma partners focusing on innovative therapies; completes acquisitions and divestitures to optimize portfolio and geographic reach; launches new therapies and expands indications in oncology and immunology; announces strategic shifts toward higher-value biologics and rare diseases; undergoes organizational restructuring and potential rebranding moves to enhance commercial efficiency; scales manufacturing capacity and supply chain resilience in North America, Europe, and Asia; establishes or expands global partnerships for research, development, and commercialization in multiple markets. Additional context: operates across biopharmaceutical research, development, manufacturing, and commercialization; serves global healthcare providers, hospitals, clinics, and wholesale distributors; geographic footprint includes North America, Europe, Asia-Pacific, and emerging markets; founded in 1989 with headquarters in North Chicago, Illinois; has multiple subsidiaries and affiliates under AbbVie Inc. and strategic relationships with partners and contract manufacturers to support a wide therapeutic portfolio.